SIR 2024
Interventional Oncology
Karan Rao, MD
Resident Physician
University of Iowa Hospitals & Clinics
Financial relationships: Full list of relationships is listed on the CME information page.
Ajmain Chowdhury, BS
Medical Student
University of Iowa
Financial relationships: Full list of relationships is listed on the CME information page.
Francisco Donato, MD
Clinical Assistant Professor of Radiology
University of Iowa
Disclosure information not submitted.
Assim Saad Eddin, MD
Research Fellow
University of Iowa Hospitals & Clinics
Disclosure information not submitted.
Brian J. Smith, PhD
Professor, Biostatistics Core Director
Holden Comprehensive Cancer Center, University of Iowa
Disclosure information not submitted.
Gustavo Pipoca Andrade, PhD (he/him/his)
President
SOBRICE - IR Brazilian Society, Brazil
Disclosure information not submitted.
In this cohort, 37 patients had cirrhosis and HCC, and 15 patients had metastatic disease to the liver. Hepatitis C was the risk factor for cirrhosis in 25/37 (68%) patients. Colon cancer was the cause of metastasis in 10/15 (67%) patients. There was no difference in liver function between cirrhotic-HCC patients and patients with metastatic disease who underwent treatment with Y-90 TARE; median OS and PFS were higher in the cirrhotic-HCC group versus the metastatic group following Y-90 TARE (table 1).
Conclusion: Y-90 TARE is a safe modality for treating both cirrhotic-HCC and liver metastasis and did not result in hepatotoxicity at 3 months in our cohort, as assessed by A, TB, and ALBI score laboratory values. In this cohort, median OS and PFS were higher for cirrhotic-HCC patients undergoing Y-90 TARE compared to patients with liver metastasis, but that result did not reach statistical significance.